Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep:133:155151.
doi: 10.1016/j.cyto.2020.155151. Epub 2020 May 30.

COVID-19 cytokine storm: The anger of inflammation

Affiliations
Review

COVID-19 cytokine storm: The anger of inflammation

Mehdi Mahmudpour et al. Cytokine. 2020 Sep.

Abstract

Patients with COVID-19 who require ICU admission might have the cytokine storm. It is a state of out-of-control release of a variety of inflammatory cytokines. The molecular mechanism of the cytokine storm has not been explored extensively yet. The attachment of SARS-CoV-2 spike glycoprotein with angiotensin-converting enzyme 2 (ACE2), as its cellular receptor, triggers complex molecular events that leads to hyperinflammation. Four molecular axes that may be involved in SARS-CoV-2 driven inflammatory cytokine overproduction are addressed in this work. The virus-mediated down-regulation of ACE2 causes a burst of inflammatory cytokine release through dysregulation of the renin-angiotensin-aldosterone system (ACE/angiotensin II/AT1R axis), attenuation of Mas receptor (ACE2/MasR axis), increased activation of [des-Arg9]-bradykinin (ACE2/bradykinin B1R/DABK axis), and activation of the complement system including C5a and C5b-9 components. The molecular clarification of these axes will elucidate an array of therapeutic strategies to confront the cytokine storm in order to prevent and treat COVID-19 associated acute respiratory distress syndrome.

Keywords: ACE2; COVID-19; Cytokine storm; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: An award was given to Iraj Nabipour by “Novo Nordisk Pars” (The Best Innovator of Diabetes in Iran 2013). For the remaining authors none were declared.

Figures

Fig. 1
Fig. 1
SARS-CoV-2 driven ACE2 down-regulation leads to an array of complex and intertwined molecular interactions via at least four axes consisting of dysregulation of the ACE2/angiotensin II/AT1R axis, attenuation of ACE2/MasR axis, increased activation of ACE2/bradykinin B1R/DABK axis, and activation of the complement cascades, resulting to a tornado of inflammatory cytokine responses ,as described by Tisoncik et al. .
Fig. 2
Fig. 2
ACE/Angiotensin II/AT1R and ACE2/MasR axis. The SARS-CoV-2 induced imbalance of ACE2/ACE that results in AT1R-mediated inflammatory response which will be accompanied with activation of the complement system, MAPK and NF-kB. The decrement of Ang (1–7) following SARS-CoV-2-mediated ACE2 down-regulation results in attenuation of MasR function. The MasR modulates AT1R-mediated inflammatory cytokine responses. Ang-(1–7) modulates the activity of ERK 1/2 via MasR. ERK 1/2 pathway induces production of IL-10, as an anti-inflammatory cytokine. Ang II, TLR2, TLR4, TLR9, and AP-1 transcription factor induce TGF-β expression. TGF-β has a role in the differentiation of T helper 17 cells from naive CD4+ T-cells.
Fig. 3
Fig. 3
ACE2/Bradykinin B1R/DABK axis. Down-regulation of ACE2 by SARS-CoV-2 leads to increased activity of [des-Arg9]-BK (DABK) with resulting increased inflammatory cytokine responses. Safotibant is a promising drug to antagonize BKB1R.
Fig. 4
Fig. 4
The complement system activation and its inhibitors. The complement system is activated through classical, lectin and alternative pathways. The nucleocapsid protein of SARS-CoV-2 results in aberrant production of C3 through MASP-2 mediated activation of mannose-binding lectin (MBL).

References

    1. Giovanetti M., Angeletti S., Benvenuto D., Ciccozzi M. A doubt of multiple introduction of SARS-CoV-2 in Italy: a preliminary overview. J. Med. Virol. 2020 - PMC - PubMed
    1. Chen Y., Liu Q., Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J. Med. Virol. 2020;92(4):418–423. - PMC - PubMed
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China, The Lancet. 2020;395(10223):497–506. - PMC - PubMed
    1. Wong C., Lam C., Wu A., Ip W., Lee N., Chan I., Lit L., Hui D., Chan M., Chung S. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004;136(1):95–103. - PMC - PubMed
    1. Mahallawi W.H., Khabour O.F., Zhang Q., Makhdoum H.M., Suliman B.A. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8–13. - PMC - PubMed

MeSH terms